Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has developed a proprietary delivery technology platform, Encapsulated Cell Technology (ECT) to deliver therapeutic factors for the treatment of retinal diseases. The Company's lead program (Renexus®) is being clinical studied in the orphan disease macular telangiectasia (MacTel) and in glaucoma. The Company is planning to initiate a Phase III study in MacTel in 2017.